Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Eli Lilly and Company. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Community Practice Connections™: The Role of RET Alterations in NSCLC and Thyroid Cancer

Release Date: May 30, 2020
Expiration Date: May 30, 2021

Activity Overview

This online educational activity is designed to provide expert commentary regarding molecular testing for the detection of RET alterations in patients with non–small cell lung cancer (NSCLC) and thyroid cancer. This program includes clinical data supporting the use of recently approved and emerging selective RET inhibitors for the treatment of patients with RET alteration–positive NSCLC, medullary thyroid cancer (MTC), and papillary thyroid cancer (PTC). The expert faculty will share best practices in incorporating molecular testing of RET alterations throughout the treatment of patients with NSCLC, MTC, and PTC.

This activity is presented in a multimedia format that includes a series of video interviews with experts in NSCLC, MTC, and PTC integrated into text-based elements. This educational program incorporates discussions about the current role of pathologists in cancer care, demonstrates real-world application of data for patients with RET alteration–positive cancers, and addresses various clinical questions that pathologists need to consider while assessing patient samples.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Eli Lilly and Company. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This educational program is directed toward pathologists who diagnose patients with solid tumors. Other health care professionals involved in the diagnosis and management of patients with solid tumors are invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Identify the role of RET alterations in diagnosis, prognosis, and guiding treatment for non–small cell lung cancer (NSCLC) and thyroid cancer
  • Evaluate safety and efficacy data for available and emerging RET-targeted treatment options in NSCLC and thyroid cancer
  • Discuss evidence-based best practices in pathology for identifying RET alterations in NSCLC and thyroid cancer
  • Integrate current and emerging testing techniques for RET alterations into clinical scenarios for NCSLC and thyroid cancer

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Dara L. Aisner, MD, PhD
Dara L. Aisner, MD, PhD
Associate Professor
Department of Pathology
Director, Colorado Molecular Correlates Laboratory
University of Colorado School of Medicine
University of Colorado Cancer Center
Denver, CO

Disclosures: Dara L. Aisner, MD, PhD, has no relevant financial relationships with commercial interests.

Thomas J. Giordano, MD, PhD
Thomas J. Giordano, MD, PhD
Henry Clay Bryant Professor of Pathology, Endocrine Pathology
Director, Division of Molecular and Genomic Pathology
Department of Pathology
Michigan Medicine
University of Michigan
Ann Arbor, MI

Disclosures: Thomas J. Giordano, MD, PhD, has no relevant financial relationships with commercial interests.

Marc Ladanyi, MD
Marc Ladanyi, MD
Chief, Molecular Diagnostics Service
William J. Ruane Chair in Molecular Oncology
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Grant/Research Support: LOXO Oncology, Helsinn Healthcare SA.

Lynette M. Sholl, MD
Lynette M. Sholl, MD
Associate Professor, Pathology
Harvard Medical School
Associate Pathologist, Pathology
Brigham and Women’s Hospital
Boston, MA

Disclosures: Grant/Research Support: F. Hoffmann-La Roche Ltd/Genentech Inc; Consultant: EMD Serono Inc.

The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
262728293031
Filter By